Business Context and Reporting Period
Company: Phio Pharmaceuticals Corp.
Filing Type: Form 8-K (Current Report)
Date of Report: May 31, 2023
Event: Entry into a Material Definitive Agreement for a concurrent Registered Direct Offering and Private Placement (PIPE). The transactions closed on June 2, 2023.
Key Financial Metrics and Transaction Details
Capital Raised: Approximately $3.5 million in net proceeds after deducting placement agent fees and offering expenses.
Offering Price: $4.28 per share for Common Stock and PIPE Shares.
Securities Issued:
- Registered Direct Offering: 233,646 shares of Common Stock plus accompanying long-term (Series A) and short-term (Series B) warrants exercisable for up to 467,292 shares.
- PIPE Private Placement: 72,000 shares of Common Stock, 628,935 pre-funded warrants, and accompanying warrants exercisable for up to 1,401,870 shares.
- Placement Agent Warrants: Warrants to purchase up to 70,094 shares issued to H.C. Wainwright & Co., LLC.
Warrant Terms: Series A and Series B warrants have an exercise price of $4.03 per share. Placement Agent Warrants have an exercise price of $5.35 per share.
Material Changes and Fees
Transaction Costs:
- Cash Fee: 7.5% of gross proceeds paid to the Placement Agent.
- Management Fee: 1.0% of gross proceeds.
- Expenses: $60,000 for non-accountable expenses and $15,950 for clearing fees.
Lock-Up Provisions: The Company is prohibited from issuing or announcing the issuance of Common Stock or equivalents for 30 days following the effective date of the registration statement. A prohibition on Variable Rate Transactions extends for one year from the effective date.
Outlook, Risks, and Contingencies
Registration Rights: The Company agreed to file a registration statement for resale of the PIPE securities within 10 calendar days, with an effectiveness deadline of 40 days (or 70 days if a full SEC review is required). Failure to meet these deadlines may result in liquidated damages.
Fundamental Transactions: In the event of a Fundamental Transaction (e.g., merger, acquisition), warrant holders (excluding pre-funded warrants) may be entitled to consideration equal to the Black-Scholes value of their warrants.
Financial Performance: This filing is a current report regarding a capital raise and does not contain revenue, profit, cash flow, or margin data for a specific reporting period.
Investor Verification Checklist
- Verify the final closing date and total gross proceeds raised (filing states net proceeds of ~$3.5 million).
- Confirm the effective date of the registration statement filed for the PIPE securities to determine the expiration of lock-up periods.
- Review the full text of the Securities Purchase Agreements (Exhibits 10.1 and 10.2) for specific redemption rights or anti-dilution provisions not detailed in the summary.
- Monitor the Company's cash position post-closing to assess runway for ongoing operations.
- Check for any subsequent filings regarding the exercise of pre-funded warrants, which could impact share count and dilution.